Antimalarials linked to retinal toxicity

Article

Hydroxychloroquine and chloroquine are strongly associated with retinal toxicity in patients with a lean body weight,

Hydroxychloroquine and chloroquine are strongly associated with retinal toxicity in patients with a lean body weight, according to a recent study published in the Archives of Ophthalmology.

The clinical findings suggested doctors should consider patient's body weight before administering either of the anti-malarial treatments. Dr Micheal Michaelides, et al, Oregon Retinal Degeneration Center, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA, studied 16 women aged between 44–85 for 7 years.

The research was carried out using fundus photography, visual field testing and electrophysiologic assessment on all patients. Six patients received spectral domain optical coherence tomography (OCT) and 4 patients received fundus autofluorescence imaging.

Results indicated that all patients had bilateral macular cone dysfunction. The most common symptom observed was difficulty reading and the fundus results varied from mild retinal pigment epithelial changes to bull's-eye maculopathy.

To lower the risk of retinal toxicity the findings advise the consideration of the patient's lean bodyweight when calculating the daily dosage of hydroxychloroquine sulphate and chloroquine phosphate.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.